Infectious disease: A neutralizing human monoclonal antibody protects African green monkeys from Hendra virus challenge

Science Translational Medicine

Volumn 3, Issue 105, 2011, Pages

  Bossart, Katharine N ^a   Geisbert, Thomas W ^b,c   Feldmann, Heinz ^d,e   Zhu, Zhongyu ^f,g   Feldmann, Friederike ^d   Geisbert, Joan B ^b,c   Yan, Lianying ^h   Feng, Yan Ru ^h   Brining, Doug ^d   Scott, Dana ^d   Wang, Yanping ^f,g   Dimitrov, Antony S ⁱ   Callison, Julie ^d   Chan, Yee Peng ^h   Hickey, Andrew C ^a   Dimitrov, Dimiter S ^f   Broder, Christopher C ^h   Rockx, Barry ^c,d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF MANITOBA   (Canada)

^f NATIONAL CANCER INSTITUTE   (United States)

^g SAIC FREDERICK INC   (United States)

^h UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

ⁱ Profectus BioSciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M102.4; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CHLOROCEBUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; HENDRA VIRUS; HENDRA VIRUS INFECTION; IMMUNE RESPONSE; INFECTION PREVENTION; LOW DRUG DOSE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TOXICITY TESTING; TREATMENT DURATION; TREATMENT OUTCOME; ANIMAL; CERCOPITHECUS; HENIPAVIRUS INFECTION; HUMAN; PATHOGENICITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CERCOPITHECUS AETHIOPS; HENDRA VIRUS; HENIPAVIRUS INFECTIONS; HUMANS;

EID: 80054788706     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002901     Document Type: Article

References (36)

1. B. T. Eaton, C. C. Broder, D. Middleton, L. F. Wang, Hendra and Nipah viruses: Different and dangerous. Nat. Rev. Microbiol. 4, 23-35 (2006).
2. M. A. Mayo, A summary of taxonomic changes recently approved by ICTV. Arch. Virol. 147, 1655-1663 (2002).
3. H. Field, P. Young, J. M. Yob, J. Mills, L. Hall, J. Mackenzie, The natural history of Hendra and Nipah viruses. Microbes Infect. 3, 307-314 (2001).
4. C. Iehlé, G. Razafitrimo, J. Razainirina, N. Andriaholinirina, S. M. Goodman, C. Faure, M. C. Georges-Courbot, D. Rousset, J. M. Reynes, Henipavirus and Tioman virus antibodies in pteropodid bats, Madagascar. Emerg. Infect. Dis. 13, 159-161 (2007).
5. K. N. Bossart, M. Tachedjian, J. A. McEachern, G. Crameri, Z. Zhu, D. S. Dimitrov, C. C. Broder, L. F. Wang, Functional studies of host-specific ephrin-B ligands as henipavirus receptors. Virology 372, 357-371 (2008).
6. K. A. Bishop, C. C. Broder, in Emerging Infections,W.M. Scheld, S.M.Hammer, J. M. Hughes, Eds. (American Society for Microbiology, Washington, DC, 2008), pp. 155-187.
7. S. P. Luby, M. J. Hossain, E. S. Gurley, B. N. Ahmed, S. Banu, S. U. Khan, N. Homaira, P. A. Rota, P. E. Rollin, J. A. Comer, E. Kenah, T. G. Ksiazek, M. Rahman, Recurrent zoonotic transmission of Nipah virus into humans, Bangladesh, 2001-2007. Emerg. Infect. Dis. 15, 1229-1235 (2009).
8. Nipah virus, fatal - Bangladesh: Faridpur. Pro-MED-mail (International Society for Infectious Diseases, January 22, 2010, archive no. 20100122.0250); http://www.promedmail.org
9. Nipah encephalitis, human - Bangladesh: Rangpur (05). Pro-MED-mail (International Society for Infectious Diseases, March 8, 2011, archive no. 20110308.0756); http://www. promedmail.org
10. H. E. Field, P. C. Barratt, R. J. Hughes, J. Shield, N. D. Sullivan, A fatal case of Hendra virus infection in a horse in north Queensland: Clinical and epidemiological features. Aust. Vet. J. 78, 279-280 (2000).
11. J. N. Hanna, W. J. McBride, D. L. Brookes, J. Shield, C. T. Taylor, I. L. Smith, S. B. Craig, G. A. Smith, Hendra virus infection in a veterinarian. Med. J. Aust. 185, 562-564 (2006).
12. Hendra virus, equine - Australia (03): Queensland, human exposure. Pro-MED-mail (International Society for Infectious Diseases, August 20, 2009, archive no. 20090821.2963); http://www.promedmail.org
13. E. G. Playford, B. McCall, G. Smith, V. Slinko, G. Allen, I. Smith, F. Moore, C. Taylor, Y. H. Kung, H. Field, Human Hendra virus encephalitis associated with equine outbreak, Australia, 2008. Emerg. Infect. Dis. 16, 219-223 (2010).
14. Hendra virus, equine - Australia (03): Queensland, human exposure. Pro-MED-mail (International Society for Infectious Diseases, May 22, 2010, archive no. 20100522.1699); http://www.promedmail.org
15. Hendra virus, equine - Australia (04): Queensland, human exposure. Pro-MED-mail (International Society for Infectious Diseases, May 24, 2010, archive no. 20100522.1724); http://www.promedmail.org
16. "Vets warn on spread of hendra virus," Melton Weekly, 18 May 2010; http://www.meltonweekly. com.au
17. Hendra virus, equine - Australia (26): New South Wales. Pro-MED-mail (International Society for Infectious Diseases, August 30, 2011, archive no. 20100527.1761); http://www. promedmail.org
18. K. N. Bossart, J. Bingham, D. Middleton, Targeted strategies for henipavirus therapeutics. Open Virol. J. 1, 14-25 (2007).
19. Hendra virus, equine - Australia (05): Queensland, human exposure. Pro-MED-mail (International Society for Infectious Diseases, May 27, 2010, archive no. 20100527.1761); http://www.promedmail.org
20. M. I. Bonaparte, A. S. Dimitrov, K. N. Bossart, G. Crameri, B. A. Mungall, K. A. Bishop, V. Choudhry, D. S. Dimitrov, L. F. Wang, B. T. Eaton, C. C. Broder, Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc. Natl. Acad. Sci. U.S.A. 102, 10652-10657 (2005).
21. O. A. Negrete, E. L. Levroney, H. C. Aguilar, A. Bertolotti-Ciarlet, R. Nazarian, S. Tajyar, B. Lee, EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature 436, 401-405 (2005).
22. O. A. Negrete, M. C. Wolf, H. C. Aguilar, S. Enterlein, W. Wang, E. Mühlberger, S. V. Su, A. Bertolotti-Ciarlet, R. Flick, B. Lee, Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus. PLoS Pathog. 2, e7 (2006).
23. K. A. Bishop, T. S. Stantchev, A. C. Hickey, D. Khetawat, K. N. Bossart, V. Krasnoperov, P. Gill, Y. R. Feng, L. Wang, B. T. Eaton, L. F. Wang, C. C. Broder, Identification of Hendra virus G glycoprotein residues that are critical for receptor binding. J. Virol. 81, 5893-5901 (2007).
24. Z. Zhu, A. S. Dimitrov, K. N. Bossart, G. Crameri, K. A. Bishop, V. Choudhry, B. A. Mungall, Y. R. Feng, A. Choudhary, M. Y. Zhang, Y. Feng, L. F. Wang, X. Xiao, B. T. Eaton, C. C. Broder, D. S. Dimitrov, Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J. Virol. 80, 891-899 (2006).
25. Z. Zhu, K. N. Bossart, K. A. Bishop, G. Crameri, A. S. Dimitrov, J. A. McEachern, Y. Feng, D. Middleton, L. F. Wang, C. C. Broder, D. S. Dimitrov, Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J. Infect. Dis. 197, 846-853 (2008).
26. K. N. Bossart, Z. Zhu, D. Middleton, J. Klippel, G. Crameri, J. Bingham, J. A. McEachern, D. Green, T. J. Hancock, Y. P. Chan, A. C. Hickey, D. S. Dimitrov, L. F. Wang, C. C. Broder, A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute Nipah virus infection. PLoS Pathog. 5, e1000642 (2009).
27. T. W. Geisbert, K. M. Daddario-DiCaprio, A. C. Hickey, M. A. Smith, Y. P. Chan, L. F. Wang, J. J. Mattapallil, J. B. Geisbert, K. N. Bossart, C. C. Broder, Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection. PLoS One 5, e10690 (2010).
28. B. Rockx, K. N. Bossart, F. Feldmann, J. B. Geisbert, A. C. Hickey, D. Brining, J. Callison, D. Safronetz, A. Marzi, L. Kercher, D. Long, C. C. Broder, H. Feldmann, T. W. Geisbert, A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment. J. Virol. 84, 9831-9839 (2010).
29. A. J. Hessell, L. Hangartner, M. Hunter, C. E. Havenith, F. J. Beurskens, J. M. Bakker, C. M. Lanigan, G. Landucci, D. N. Forthal, P.W.Parren, P.A.Marx, D. R. Burton, Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101-104 (2007).
30. J. A. McEachern, J. Bingham, G. Crameri, D. J. Green, T. J. Hancock, D. Middleton, Y. R. Feng, C. C. Broder, L. F. Wang, K. N. Bossart, A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats. Vaccine 26, 3842-3852 (2008).
31. J. Pallister, D. Middleton, L. F. Wang, R. Klein, J. Haining, R. Robinson, M. Yamada, J. White, J. Payne, Y. R. Feng, Y. P. Chan, C. C. Broder, A recombinant Hendra virus G glycoproteinbased subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine 29, 5623-5630 (2011).
32. V. Guillaume, H. Contamin, P. Loth, I. Grosjean, M. C. Courbot, V. Deubel, R. Buckland, T. F. Wild, Antibody prophylaxis and therapy against Nipah virus infection in hamsters. J. Virol. 80, 1972-1978 (2006).
33. V. Guillaume, K. T. Wong, R. Y. Looi, M. C. Georges-Courbot, L. Barrot, R. Buckland, T. F. Wild, B. Horvat, Acute Hendra virus infection: Analysis of the pathogenesis and passive antibody protection in the hamster model. Virology 387, 459-465 (2009).
34. Y. P. Chan, L. Yan, Y. R. Feng, C. C. Broder, Preparation of recombinant viral glycoproteins for novel and therapeutic antibody discovery. Methods Mol. Biol. 525, 31-58, xiii (2009).
35. K. N. Bossart, J. A. McEachern, A. C. Hickey, V. Choudhry, D. S. Dimitrov, B. T. Eaton, L. F. Wang, Neutralization assays for differential henipavirus serology using Bio-Plex protein array systems. J. Virol. Methods 142, 29-40 (2007).
36. Acknowledgments: We thank the staff of the Rocky Mountain Veterinary Branch for animal care and veterinary support. We thank Y. Feng for help with the m102.4 production. Funding: These studies were supported in part by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH, and in part by the Department of Health and Human Services, NIH, grants AI082121 and AI057159 (to T.W.G.) and AI054715 and AI077995 (to C.C.B.), and the Intramural Biodefense Program of the National Institute of Allergy and Infectious Diseases, the Intramural Program of the National Cancer Institute, Center for Cancer Research, and by federal funds from the National Cancer Institute, NIH, under contract N01-CO-12400. Author contributions: K.N.B., B.R., H.F., C.C.B., and T.W.G. designed the studies. B.R., H.F., T.W.G., F.F., D.B., and J.B.G. contributed to performance of experiments and data collection and analysis. B.R., H.F., and T.W.G. performed gross pathological analysis. B.R., K.N.B., A.C.H., and J.C. performed serological and nucleic acid analysis experiments and data collection. Y.-P.C. provided critical reagents and contributed to assay design. L.Y., Y.-R.F., and Y.W. produced, purified, and quality controlled the m102.4 monoclonal antibody. Z.Z. and D.S.D. provided critical reagents, contributed to study design, and reviewed and edited the manuscript. D.S. performed histological analysis and J.B.G. and D.B. facilitated the conduct of the in vivo animal studies. A.S.D. provided the analysis of the antibody pharmacokinetics studies. K.N.B., C.C.B., B.R., H.F., and T.W.G. wrote and edited the manuscript. C.C.B. prepared the final versions of the manuscript and supplementary material. Competing interests: C.C.B. and D.S.D. are U.S. federal employees, and D.S.D., Z.Z., and C.C.B. are coinventors on U.S. patent 7,988,971, "Human monoclonal antibodies against Hendra and Nipah viruses"; assignees are the United States of America as represented by the Department of Health and Human Services (Washington, DC) and Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. (Bethesda, MD). All other authors declare no competing interests. The opinions or assertions contained herein are the private ones of the author(s) and are not to be construed as official or reflecting the views of the Department of Defense, the Uniformed Services University of Health Sciences, and the National Institutes of Allergy and Infectious Diseases, NIH.